Market Overview

UPDATE: Goldman Sachs Upgrades Stryker Corporation to Buy on Organic Growth, Capital Allocation

Related SYK
Benzinga's Top Downgrades
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
After Some Turbulence, NuVasive Appears To Be On A Better Flightpath (Seeking Alpha)

Goldman Sachs raised its rating on Stryker Corporation (NYSE: SYK) from Neutral to Buy and increased its price target from $55 to $68.

Goldman Sachs noted, "Our thesis calls for improvements in both operational and financial performance as follows: (1) new CEO and a reset of expectations for 2013; (2) strong product portfolio/pipeline and diversified revenue base offer multiple growth opportunities; (3) shareholder-friendly capital allocation with a greater orientation to cash returns; (4) cost and quality control initiatives remain a source of margin opportunity; and (5) attractive relative valuation compared to other large-cap MedTech firms in our coverage universe."

Stryker Corporation closed at $54.57 on Monday.

Latest Ratings for SYK

Sep 2015NeedhamDowngradesBuyHold
Aug 2015Stifel NicolausMaintainsBuy
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (SYK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters